Effects of moderate-intensity concurrent exercise training on cardiovascular risk factors in patients with chronic kidney disease undergoing hemodialysis: a randomized control trial

Saeid Shokati Basir,Bahman Mirzaei

DOI: https://doi.org/10.1007/s11332-022-00911-6

2022-03-02

Sport Sciences for Health

Abstract:PurposePatients with chronic kidney disease (CKD) undergoing hemodialysis are generally physically inactive, have a high mortality rate due to cardiovascular disease (CVD), and may benefit from an exercise program to improve CKD-induced CVD causatives. Our purpose was to examine the effects of concurrent exercise training on CVD risk factors including peak oxygen uptake (V˙O2peak$$\dot{V}{\text{O}}_{{2}} {\text{peak}}$$), C-reactive protein (CRP), asymmetric isomer of dimethylarginine (ADMA), fibroblast growth factor-23 (FGF-23), and glycated hemoglobin (HbA1c) in end-stage renal disease patients undergoing hemodialysis.MethodsWe performed a 12-week randomized controlled feasibility study examining the effects of a concurrent aerobic and resistance training on the aforementioned variables. Patients (age = 50.1 ± 14 years) randomized to either exercise training group (ET) (2 day/week of aerobic training with 40–60% V˙O2peak$$\dot{V}{\text{O}}_{{2}} {\text{peak}}$$ during dialysis; and 2 day/week of resistance training with rating of perceived exertion of 10–15 of 20 during rest), or untrained control group (CON).ResultsThe employed exercise increased V˙O2peak$$\dot{V}{\text{O}}_{{2}} {\text{peak}}$$ (13.8%, p = 0.005) and decreased plasma levels of CRP (− 18.7%, p = 0.01), ADMA (− 9.1%, p = 0.01), FGF-23 (− 10.5%, p = 0.05), and HbA1c (− 7.9%, p = 0.01). Also, the change in V˙O2peak$$\dot{V}{\text{O}}_{{2}} {\text{peak}}$$ and HbA1c level in ET group was significantly greater than that of CON group (p = 0.04 and 0.05, respectively).ConclusionThese findings provide compelling evidence that combined aerobic and resistance exercise could be considered as a potent stimulus to induce adaptations in aerobic capacity and decrease CVD risk factors in patients with chronic kidney disease.